According to Patra et al. (2022), through a robust systematic network and meta-analysis, probiotics or probiotic-derived bacteriocins could interact directly with immune enzymes involved in colorectal cancer (CRC) pathogenesis, such as COX-2, and even modulate nod-like receptor protein-3 (NLRP3) or NF-kB pathways, reducing CRC-associated inflammation [7]. This evidence concerns the gene NFKB1 and colorectal carcinoma.